Live from Singapore: China in the Fast Lane - How to play and win in the world's hottest emerging market
Join us Thursday 18th July 2019 16:00 SGT/ 16:00 CST / 17:00 JST
Register now for this live webinar where Pei Li Teh and Wan Ling Neo will explore China's evolving healthcare environment. In the webinar they will highlight the key changes affecting pharma and demonstrate how to build the market understanding required to launch a brand effectively in this exciting region.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).
China in the Fast Lane: How to play and win in the world's hottest emerging market
Watch this webcast where Marc Yates and Helen Ansell explore China's evolving healthcare environment. The webcast highlights the key changes affecting pharma and demonstrates how to build the market understanding required to launch a brand effectiviely in this exciting region.
Webcast: Rich in potential - Exploring the opportunity for nutritionals in emerging markets
A shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories, attention is turning to emerging markets. Join Research Partnership's emerging market experts Paul Reed and Kira Pillai for our upcoming live webinar ‘Rich in potential: Exploring the opportunity for nutritionals in emerging markets’ in which they will explore the challenges and opportunities for the nutritionals sector in some of the world’s fastest growing markets.